ALOX5AP and obesity due to melanocortin 4 receptor deficiency: In obesity, a beneficial effect of pharmacological FLAP inhibition has been attributed to an induction of AMP-activated protein kinase phosphorylation and a concomitant decrease in hormone-sensitive lipase activity accompanied by reduced steatosis [14].